A.d.a.m. Innovations

What A.d.a.m. Innovations does

A.D.A.M. Innovations Co. (formerly Genesis Healthcare Co.) is a Japanese genomics and AI-health prediction company founded in 2004 and headquartered in Tokyo with operations across Japan, Singapore, and Taiwan. It operates three main business pillars: consumer-facing DTC genetic testing through the GeneLife brand, clinical-grade diagnostic services via GenesisPro, and a B2B genomic-data platform called GenesisGaia. As of 2026 the company reports more than 2.9 million genetic tests performed and approximately 2.8 million user accounts, giving it a stated 74% share of the Japan DTC genetic testing market.

The company's underlying technology is built on a proprietary genomic database of more than 400,000 samples and 74 patents covering AI prediction models. Its flagship AI offering, GeneAI Forecast, combines DNA, biomarker, and lifestyle data to produce disease-risk predictions across 15 conditions including lifestyle diseases, cancers, and rare disorders. The platform integrates with Illumina sequencing hardware (including NovaSeq X Plus and iSeq 100) and runs on AWS infrastructure. Adjacent platform products include GeneLink (ad-tech leveraging genetic attributes), GeneLock (genetic-data protection/consent infrastructure), and GeneLife Haplo (relative matching with a database of 300,000-plus relatives). The company holds CAP clinical-lab accreditation, JIS Q 15001 Privacy Mark, and is a member of the Association of Genetic Information and the Global Alliance for Genomics and Health (GIGR).

A.D.A.M. generates revenue through multiple channels: direct-to-consumer kit sales (both online and through pharmacy retail including Sundrug), subscription services under the CONNECT family, clinical testing fees from medical institutions, enterprise licensing of the GenesisGaia platform to pharmaceutical and research organizations, and advertising revenue via GeneLink. Strategic partnerships with AWS, Illumina, Kansai Medical University, NTT Precision Medicine, and Japan's National Institute of Genetics provide distribution and research scale. The November 2025 rebranding from Genesis Healthcare to A.D.A.M. Innovations marks an explicit strategic repositioning toward being an AI-first genomics platform rather than primarily a consumer testing brand.

Name

A.d.a.m. Innovations

Legal name

Genesis Healthcare Co.

Website

https://adam-innovations.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

A.D.A.M. Innovations is a Tokyo-based genomics and AI company operating consumer DTC testing (GeneLife), clinical diagnostics (GenesisPro), and a B2B genomic-data platform (GenesisGaia) across Japan, Singapore, and Taiwan, serving consumers, medical institutions, and pharmaceutical/research enterprises.

Ownership category

akta.pro rank

Product category

Genetic Testing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Genetic testing services
• Genomic sequencing platforms
• Consumer DNA testing
• Clinical genetic diagnostics
• Bioinformatics data platforms

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Direct-to-Consumer Genetic Testing: Sale of genetic testing kits directly to consumers through e-commerce channels and mobile apps, including health, ancestry, diet, sports, beauty and skincare tests, as well as Whole Genome Sequencing (WGS) services.
2. Subscription Services: Monthly subscription plans (Genesis CONNECT, WGS CONNECT, Haplo CONNECT) providing ongoing access to genetic results, value-added features, data storage, and continuous updates as genomic science evolves.
3. B2B Genomic Data Platform (GenesisGaia): Licensing access to genomic and phenotypic data for R&D purposes to life sciences researchers, pharmaceutical companies, and product development organizations.
4. Clinical Genetic Testing Services (GenesisPro): Genetic testing services provided to medical professionals and healthcare institutions through Genesis Institute of Genetic Research (GIGR).
5. GeneLink Ad-Tech Platform: Precision marketing platform leveraging genetics and lifestyle data for targeted advertising, creating a new revenue stream in the advertising technology sector.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

A.D.A.M. Innovations provides AI-powered genomic sequencing, clinical diagnostics, direct-to-consumer DNA tests, and population-scale genomic data platforms. Its offerings span at-home genetic testing kits (GeneLife brand) for health, ancestry, diet, beauty, sports and longevity; the B2B GenesisGaia genomic R&D platform for life sciences and pharmaceutical companies; clinical testing through a CAP-accredited laboratory (GenesisPro); the GeneLock genetic data protection platform; and the GeneLink AI ad-tech platform.

Product overview

A.D.A.M. Innovations operates as a diversified genomics company offering a platform-plus-services model. The core consumer brand GeneLife provides direct-to-consumer genetic testing across multiple product tiers (standard kits, WGS, ancestry), supplemented by subscription services (Genesis CONNECT, WGS CONNECT, Haplo CONNECT, Diet CONNECT) that add ongoing value through AI-powered features like GeneAI Forecast. The enterprise segment spans GenesisGaia (population genomic R&D platform for researchers and pharma), GenesisPro (CAP-accredited clinical testing laboratory), GeneLink (genetics-powered advertising platform), and GeneLock (genetic data protection). The company holds 74 patents for AI prediction models and has completed over 2.9 million genetic tests, commanding 74% DTC market share in Japan.

Differentiator

Problem solved

Functional benefit

Brands

• GenesisGaia: Asia's first and largest genomic platform for R&D, servicing researchers in life sciences, pharmaceutical, beauty, health, food and product development.
• GenesisPro
• GeneLife
• GeneLock
• GeneLink

Products and services

• GenesisGaia Asia's first and largest population genomic R&D platform serving researchers in life sciences, pharmaceutical, beauty, health, food, and product development with access to 400,000+ samples enriched with phenotypic data. Powered with AI, advanced visualizations, screening tools, and prediction algorithms for medical and drug discovery and service personalization.
• GenesisPro Clinical genetic testing and screening services offered through the Genesis Institute of Genetic Research (GIGR), a CAP-accredited and Japanese CLIA-registered laboratory in Tokyo. Provides one-stop service from sample preparation through sequencing to bioinformatics and data science for medical professionals and researchers at competitive cost in Japan and Asia.
• GeneLock World's first genetic data protection platform combining de-sequencing, decentralized protection, and authorized reconstruction controls. Fragmenting and distributing genomic information across independent secure environments to prevent meaningful exposure while enabling reconstruction only under authorized conditions. Designed for government genomic programs, large-scale databases, research institutions, life sciences organizations, and consumer applications.
• GeneLink Groundbreaking ad-tech platform combining genetics, lifestyle data, and AI for precision marketing. Leverages biological predispositions to create deeper connections between brands and audiences, built on the largest genomic database of the Japanese population with users benefiting directly from their participation.
• COVID-19 PCR Testing Convenient at-home COVID-19 PCR testing service with saliva sample collection, doctor consultation, and smartphone-accessible results. Includes COVID-19 & Influenza Combo PCR testing, analyzed under strict international and Japanese standards at the company's laboratory in Tokyo.
• GeneLife WGS At-home Whole Genome Sequencing test analyzing over 6,500 items including genetic disease risks, constitution, rare diseases, hereditary conditions, cancers, and lifestyle-related diseases. Decodes about 30,000 genes and more than 6.9 million gene mutations, with online counseling by healthcare professionals. Uses Illumina NovaSeq X Plus sequencing with 30x coverage.
• GeneLife Haplo 3.0 Asia-focused ancestry kit featuring ethnicity mix analysis, ancestral migration paths, DNA Relatives Matching, and Prehistorical Ancestry including Neanderthal and Jōmon people lineage detection. Developed through 7 years of joint research with the National Institute of Genetics (NIG) Japan. Priced at SGD 199 in Singapore.
• GeneLife Diet CONNECT Japan's first genetic result-driven AI chatbot providing personalized dietary insights based on individual genetic profiles. Delivers customized meal suggestions, weight management strategies, and lifestyle recommendations considering genetic influences on metabolism, food sensitivities, and nutrient absorption.
• ALUNAE World's first AI genomic-based skincare line designed to address Japanese and Asian environmental skin aging. Combines genetic insights with AI for personalized skincare recommendations.

Quantifiable outcome

• 2.9 million+ genetic tests performed to date
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Kepios / Simon KempminorGTM or Marketing Partner · 22 May 2025Simon Kemp from Kepios shared insights on global and Japanese digital and AI trends at Digital Meet Up event. Kepios 2025 report utilized for market understanding.
• AWS JapanminorGTM or Marketing Partner · 7 February 2025Genesis Healthcare participated in AWS Japan Generative AI Frontier Meetup, sharing insights on integrating genomics big data with generative AI and chatbots with over 100 participants.
• Kansai Medical UniversitycoreStrategic or Co-development Partner · 9 October 2024First joint research collaboration in Japan integrating genomic big data held by both institutions and applying AI to accelerate new genomic discoveries across diseases pertaining to psychiatric, immune, cardiovascular and respiratory diseases. GenesisGaia serves as the AI platform foundation with 400,000+ samples.
• IlluminacoreTechnology or Integration · 26 August 2024Incorporation of Illumina NovaSeq X Plus sequencing technology into laboratory infrastructure for enhanced Whole Genome Sequencing capabilities with increased capacity and speed.
• AWS (Amazon Web Services)coreTechnology or Integration · 13 May 2024GenesisGaia services broadened through AWS to facilitate global research initiatives with Asian genomic data. Utilization of AWS HealthOmics and AWS Marketplace for scalable genomic data processing and global accessibility.
• NTT Precision MedicinecoreStrategic or Co-development PartnerA.D.A.M. Innovations enables pharmacogenomics capabilities for NTT Precision Medicine, supporting personalized medicine initiatives.
• National Institute of Genetics (NIG) JapancoreStrategic or Co-development Partner7 years of joint research with NIG applied to ethnicities and ancestral migrations, developing Japanese and Asian genetic footprint data (haplogroups) for GeneLife Haplo ancestry service.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• 23andMe: Largest US-based direct-to-consumer genetic testing company offering ancestry, health, and trait reports. Directly comparable to GeneLife's DTC business model and competes for the same end-customer use cases, though 23andMe lacks A.D.A.M.'s Asian population depth.
• Ancestry: Global leader in consumer ancestry and family-history genetic testing with massive DNA relatives database. Closest comparable to GeneLife Haplo 3.0's ancestry + relative-matching offering, though focused on Western populations.
• Veritas Genetics: US-based whole genome sequencing company offering consumer and clinical WGS services. Directly comparable to GeneLife WGS as an at-home 30x WGS product with clinical-grade interpretation.
• Prenetics: Hong Kong-headquartered genomics and precision health company offering DTC genetic testing and clinical diagnostics across Asia. Closest geographic and business-model peer to A.D.A.M.'s Asian-population-focused consumer and clinical testing stack.
• MyHeritage: Israel-based DTC genetic testing company offering ancestry, health, and family-tree services. Direct peer in consumer DNA testing with international footprint overlapping A.D.A.M.'s Singapore and Taiwan markets.
• Helix: US-based population genomics platform offering white-label DNA testing, clinical-grade sequencing, and a data marketplace model. Closest peer to A.D.A.M.'s hybrid platform-plus-consumer strategy (GenesisGaia + GeneLife).
• Color Health: US-based population genomics and clinical genetic testing company offering hereditary cancer and pharmacogenomics testing. Directly comparable to GenesisPro's clinical testing and to A.D.A.M.'s pharmacogenomics AI capabilities.
• Macrogen: Korea-based genomic services and clinical diagnostics company offering sequencing, microarray, and bioinformatics services. Comparable to GenesisPro/GIGR's clinical testing and sequencing-services capabilities in the Asian market.

Broad incumbents

• Illumina: Global leader in DNA sequencing technology and a key infrastructure provider to A.D.A.M. (NovaSeq X Plus). Not a direct DTC competitor, but a broader incumbent whose platform choices shape A.D.A.M.'s cost structure and roadmap.
• BGI Group: China-headquartered global genomics conglomerate covering sequencing services, clinical diagnostics, and population genomics at massive scale. Competes broadly in Asian genomics but with much larger scale and broader portfolio than A.D.A.M.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/GeneLife_JP
• LinkedInlinkedin.com/company/adaminnovations
• Instagraminstagram.com/genelife_official

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A.d.a.m. Innovations